About Event
Welcome to the 3rd Annual Hemophilia Drug Development Summit
With the approval of Hemlibra, clinical investigations into Concizumab and FItusiran, and of course the oncoming gene therapy revolution, we are seeing a race to market for the better and more effective long-acting or curative hemophilia and bleeding disorder therapies.
This meeting offers a wealth of relevant content covering a plethora of treatment options to help you overcome your specific challenges. Join industry leaders to:
Discuss the patient/payer paradigm and gain an insight into this ongoing challenge within the hemophilia field
Understand the potential of gene therapy for treating bleeding disorders in a small subset of patients as the therapeutic activity expands
Analyze the novel drugs available to treat acquired hemophilia and how diagnosis can be improved to avoid joint damage
Determine effective treatments for the inhibitor population by overcoming the immune response to factor replacement treatment
Learn how to overcome efficacy challenges in extended half-life therapies by individualizing treatments for patients and measuring pharmacokinetics
Discuss the commercial, regulatory and market access currently available and how this can aid patients in getting the treatment that they need